3+ hour, 1+ min ago   (711+ words) A long-term study reveals that blinatumomab significantly enhances survival rates in infants with KMT2A-rearranged ALL, offering hope for improved treatment outcomes. Findings from a long-term follow-up study on the use of blinatumomab (Blincyto) in infants with KMT2A-rearranged acute lymphoblastic leukemia…...

1+ mon, 3+ week ago   (411+ words) At the recommended phase 2 dose of 9 mg/kg per cycle, among 32 patients, 24 (75%) achieved complete response (CR). Of the 23 patients who had post-induction bone marrow metastases, 22 achieved CR. This high response rate persisted in patients with high disease burden, including those…...

4+ mon, 3+ week ago   (95+ words) Lantern Pharma advances pediatric CNS cancer treatment with FDA guidance on LP-184 trial, targeting rare tumors and enhancing therapy with spironolactone. Last month, the FDA cleared a new clinical trial for LP-184 plus spironolactone in glioblastoma multiforme (GBM).3The planned phase…...

8+ mon, 1+ week ago   (577+ words) BCB-276 has earned regenerative medicine advanced therapy designation from the FDA in diffuse intrinsic pontine glioma, an incurable pediatric tumor. BCB-276 has earned regenerative medicine advanced therapy designation from the FDA in diffuse intrinsic pontine glioma, an incurable pediatric tumor....

9+ mon, 6+ day ago   (422+ words) Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting. The FDA has granted breakthrough therapy designation to BCB-276 for the treatment of diffuse intrinsic…...

10+ mon, 5+ day ago   (369+ words) Hedy Lee Kindler, MD, shares new mesothelioma guidelines that have been released by the American Society of Clinical Oncology. Hedy Lee Kindler, MD, shares new mesothelioma guidelines that have been released by the American Society of Clinical Oncology. In recent…...